KEAP1 and neoplasm: Drawing inspiration from the erythropoietin (EPO) biosynthetic process, an EPO enhancer is constructed to impart the EPO‐Keap1 plasmid (DNA) with tumor hypoxia‐activated functionality, disrupting the redox homeostasis of the TME.